Colby Pharmaceutical Announces Publication of JVRS-100 use as Potent Immune Activating Adjuvant in Combination with H5N1 Influenza Vaccine  
1/9/2012 6:05:23 AM

SAN JOSE, Calif.--(BUSINESS WIRE)--Colby Pharmaceutical Company (CPC) today announced publication of new results showing that a single dose of JVRS-100 adjuvanted H5N1 influenza vaccine enhanced-immune responses, -dose sparing, and -cross-clade influenza virus protection. This publication, entitled, “Cationic liposome-DNA complexes (CLDC) adjuvant enhances the immunogenicity and cross-protective efficacy of a pre-pandemic influenza A H5N1 vaccine in mice,” appears in the journal Vaccine, 30(2):254-64, 2012.